TradingView
AlenCiken
2020年7月17日上午10點13分
enrolling patients in a Phase 1 #ClinicalTrial
NASDAQ:HTBX
60
描述
⋅
2020年7月17日上午10點13分
We have recently begun enrolling patients in a Phase 1 #ClinicalTrial with a new #oncology candidate. PTX-35 is an antibody that targets an entirely novel receptor involved in the immune response to #cancer.
clinicaltrials.gov/ct2/show/NCT04430348
Fundamental Analysis
Trend Analysis
Chart Patterns
評論
更多